Allergan to acquire AqueSys

Allergan will acquire AqueSys in an all cash transaction of $300 million, the company announced in a press release. Under the terms of the agreement, the upfront payment includes regulatory approval and commercialization milestone payments related to AqueSys' lead development programs including the Xen45 gel stent, the release said.

Full Story →